GlaxoSmithKline Biologicals is challenging the world of vaccines with its vaccines for the world. GlaxoSmithKline Biologicals (GSK Biologicals) is one of the world's leading vaccine producers. Rixensart, Belgium is the base for the GlaxoSmithKline's vaccine research, development and production. In 2005, GSK Biologicals distributed 1.2 billion doses of vaccines in 165 countries (over 3 million doses a day), both in the developing world and in industrialized countries. Worldwide, GSK Biologicals employs approximately 6,200 people.
Approximately 1,200 of these staff work in North America in manufacturing, clinical development, R&D and regulatory. Commercial development and marketing of vaccines is managed by U.S. Pharmaceuticals.
Five major new vaccines in five years
Vaccines are an area of significant growth for GSK. In the next five years, GSK Biologicals expects to launch five major new vaccines in the US: an HPV vaccine targeting cervical cancer, a vaccine against rotavirus (already approved in more than 30 countries), a vaccine to prevent pneumococcal disease, an improved flu vaccine for the elderly, and a meningitis combination vaccine for infants.